Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes | Zendy

Julio Rosenstock | Zendy; Steven E. Kahn | Zendy; Odd Erik Johansen | Zendy; Bernard Zinman | Zendy; Mark A. Espeland | Zendy; Hans J. Woerle | Zendy; Egon Pfarr | Zendy; Annett Keller | Zendy; Michaela Mattheus | Zendy; David Baanstra | Zendy; Thomas Meinicke | Zendy; Jyothis T. George | Zendy; Maximilian von Eynatten | Zendy; Darren K. McGuire | Zendy; Nikolaus Marx | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes

Author(s) -

Julio Rosenstock,

Steven E. Kahn,

Odd Erik Johansen,

Bernard Zinman,

Mark A. Espeland,

Hans J. Woerle,

Egon Pfarr,

Annett Keller,

Michaela Mattheus,

David Baanstra,

Thomas Meinicke,

Jyothis T. George,

Maximilian von Eynatten,

Darren K. McGuire,

Nikolaus Marx

Publication year - 2019

Publication title -

jama

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.688

H-Index - 680

eISSN - 1538-3598

pISSN - 0098-7484

DOI - 10.1001/jama.2019.13772

Subject(s) - medicine , glimepiride , linagliptin , type 2 diabetes , randomized controlled trial , diabetes mellitus , hazard ratio , stroke (engine) , metformin , myocardial infarction , insulin , endocrinology , confidence interval , mechanical engineering , engineering

Type 2 diabetes is associated with increased cardiovascular risk. In placebo-controlled cardiovascular safety trials, the dipeptidyl peptidase-4 inhibitor linagliptin demonstrated noninferiority, but it has not been tested against an active comparator.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research